Heron CEO acquires 34,789 shares via RSU vesting (Form 4)
Heron Therapeutics (HRTX) reported an insider transaction: CEO and Director Craig Collard acquired 34,789 shares of common stock on 10/31/2025 through settlement of restricted stock units (transaction code M) at $0.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Heron Therapeutics (HRTX) reported an insider transaction: CEO and Director Craig Collard acquired 34,789 shares of common stock on 10/31/2025 through settlement of restricted stock units (transaction code M) at $0.
Following the transaction, Collard directly owned 523,124 shares. He also beneficially owned 452,253 RSUs after the event. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 34,789 | $0.00 | $0.00 |
| Exercise | Common Stock | 34,789 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2. The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did HRTX report on Form 4?
What derivative securities does Craig Collard still hold?
What is the vesting schedule for the reported RSUs at HRTX?
What does transaction code M indicate in this HRTX Form 4?
What is the price reported for the RSU settlement?
AI-generated analysis. How Rhea-AI works. Not financial advice.